Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.

A fully-standardized EuroFlow 8-color antibody panel and laboratory procedure was stepwise designed to measure minimal residual disease (MRD) in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) patients with a sensitivity of ≤10-5, comparable to real-time quantitative polymerase chain reaction (RQ-PCR)-based MRD detection via antigen-receptor rearrangements. Leukocyte markers and the corresponding antibodies and fluorochromes were selected based on their contribution in separating BCP-ALL cells from normal/regenerating BCP cells in multidimensional principal component analyses. After 5 multicenter design-test-evaluate-redesign phases with a total of 319 BCP-ALL patients at diagnosis, two 8-color antibody tubes were selected, which allowed separation between normal and malignant BCP cells in 99% of studied patients. These 2 tubes were tested with a new erythrocyte bulk-lysis protocol allowing acquisition of high cell numbers in 377 bone marrow follow-up samples of 178 BCP-ALL patients. Comparison with RQ-PCR-based MRD data showed a clear positive relation between the percentage concordant cases and the number of cells acquired. For those samples with >4 million cells acquired, concordant results were obtained in 93% of samples. Most discordances were clarified upon high-throughput sequencing of antigen-receptor rearrangements and blind multicenter reanalysis of flow cytometric data, resulting in an unprecedented concordance of 98% (97% for samples with MRD < 0.01%). In conclusion, the fully standardized EuroFlow BCP-ALL MRD strategy is applicable in >98% of patients with sensitivities at least similar to RQ-PCR (≤10-5), if sufficient cells (>4 × 106, preferably more) are evaluated.

[1]  A Orfao,et al.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes , 2012, Leukemia.

[2]  C. E. Pedreira,et al.  Generation of flow cytometry data files with a potentially infinite number of dimensions , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[3]  A. Órfão,et al.  Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL , 1999, Leukemia.

[4]  E. Mejstrikova,et al.  Minimal Residual Disease-Based Risk Stratification in Chinese Childhood Acute Lymphoblastic Leukemia by Flow Cytometry and Plasma DNA Quantitative Polymerase Chain Reaction , 2013, PloS one.

[5]  B. Schäfer,et al.  Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia , 2008, Leukemia.

[6]  A. Órfão,et al.  BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. , 2001, Leukemia.

[7]  Yong-mei Zhu,et al.  Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia , 2013, Blood Cancer Journal.

[8]  J. Dongen,et al.  GENE REARRANGEMENTS ARE FREQUENT IN PRECURSOR-B-ACUTE LYMPHOBLASTIC LEUKEMIA BUT RARE IN NORMAL LYMPHOID CELLS , 2003 .

[9]  T. Kalina,et al.  Transfer of genomics information to flow cytometry: expression of CD27 and CD44 discriminates subtypes of acute lymphoblastic leukemia , 2005, Leukemia.

[10]  J. Dongen,et al.  Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia , 2004, Leukemia.

[11]  J. V. Dongen,et al.  T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis , 2002, Leukemia.

[12]  Alberto Orfao,et al.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. , 2015, Blood.

[13]  I. Bernstein,et al.  Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. , 1996, Blood.

[14]  Brent L Wood,et al.  Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry , 2016, Cytometry. Part B, Clinical cytometry.

[15]  Elaine Coustan-Smith,et al.  New markers for minimal residual disease detection in acute lymphoblastic leukemia. , 2011, Blood.

[16]  Maria Grazia Valsecchi,et al.  Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Mejstrikova,et al.  The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL. , 2015, Blood.

[18]  G. Basso,et al.  Expression of CD 58 in normal , regenerating and leukemic bone marrow B cells : implications for the detection of minimal residual disease in acute lymphocytic leukemia , 2003 .

[19]  B. Paiva,et al.  Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting , 2016, Cytometry. Part B, Clinical cytometry.

[20]  E. Mejstrikova,et al.  B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL , 2008, Bone Marrow Transplantation.

[21]  J. V. van Dongen,et al.  Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia : characteristics and applicability for the detection of minimal residual disease , 2006 .

[22]  Maria Grazia Valsecchi,et al.  Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia , 2012, Haematologica.

[23]  D. Campana,et al.  Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. , 2010, Blood.

[24]  A J van der Sluijs-Gelling,et al.  Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia , 2013, Leukemia.

[25]  M. Loh,et al.  Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. , 2015, Blood.

[26]  J. Dongen,et al.  MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. , 2009 .

[27]  C. Mosse,et al.  B-ALL minimal residual disease flow cytometry: an application of a novel method for optimization of a single-tube model. , 2015, American journal of clinical pathology.

[28]  M. D. Boer,et al.  Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement , 2007, Leukemia.

[29]  C. V. D. Schoot,et al.  Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR , 2002, Leukemia.

[30]  T. Kalina,et al.  EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols , 2012, Leukemia.

[31]  Barbara Buldini,et al.  Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia , 2015, Haematologica.

[32]  R. Pieters,et al.  Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood , 2014, Haematologica.

[33]  Li Gao,et al.  The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia , 2016, Leukemia & lymphoma.

[34]  Y. Hayashi,et al.  Significance of CD66c expression in childhood acute lymphoblastic leukemia. , 2014, Leukemia research.

[35]  J. V. van Dongen,et al.  MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. , 2009, Methods in molecular biology.

[36]  J. Dongen,et al.  Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring , 2008, Leukemia.

[37]  A. Porwit,et al.  Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi‐centre study comparing real‐time polymerase chain reaction and multicolour flow cytometry , 2011, British journal of haematology.

[38]  V. V. D. van der Velden,et al.  Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age‐related changes and disease‐induced shifts , 2004, Cytometry. Part B, Clinical cytometry.

[39]  Marek Omelka,et al.  Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry , 2010, Pediatric blood & cancer.

[40]  R. Stallings,et al.  Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time‐points reveals high levels of concordance between molecular and immunophenotypic approaches , 2009, British journal of haematology.

[41]  J. Cayuela,et al.  Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data , 2007, Leukemia.

[42]  T. Kalina,et al.  Myeloid antigens in childhood lymphoblastic leukemia:clinical data point to regulation of CD66c distinct from other myeloid antigens , 2005, BMC Cancer.

[43]  Michael N Dworzak,et al.  Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. , 2002, Blood.

[44]  P. Rohrlich,et al.  CD304 is preferentially expressed on a subset of B‐lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry , 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[45]  B. Wood,et al.  A novel flow cytometric assay for detection of residual disease in patients with B‐lymphoblastic leukemia/lymphoma post anti‐CD19 therapy , 2018, Cytometry. Part B, Clinical cytometry.

[46]  E. Blennow,et al.  Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia , 2009, Haematologica.

[47]  E S Costa,et al.  A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B‐cell chronic lymphoproliferative disorders , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[48]  E. Mejstrikova,et al.  High expression of cytoskeletal protein drebrin in TEL/AML1pos B-cell precursor acute lymphoblastic leukemia identified by a novel monoclonal antibody. , 2011, Leukemia research.